<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL) is an interferon (IFN)-induced molecule with apoptotic activity </plain></SENT>
<SENT sid="1" pm="."><plain>We examined gene mutations in the <z:hpo ids='HP_0011420'>death</z:hpo> domains of TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2), and in the TRAIL gene promoter in 46 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>In 23 of the 46 patients, <z:hpo ids='HP_0000001'>all</z:hpo> the coding regions of TRAIL-R2 were also examined </plain></SENT>
<SENT sid="3" pm="."><plain>However, no mutation or loss of heterozygosity was found </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, no mutation in the <z:hpo ids='HP_0011420'>death</z:hpo> domains of TRAIL-R1 and TRAIL-R2 genes, which causes amino acid change, was found in 18 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients </plain></SENT>
<SENT sid="5" pm="."><plain>Ribonuclease protection assay (RPA) and real-time quantitative polymerase chain reaction using polymorphonuclear neutrophils of five new <z:mp ids='MP_0005481'>CML</z:mp> patients showed that the TRAIL <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was very low before in vitro IFN-alpha stimulation and markedly upregulated after IFN-alpha stimulation </plain></SENT>
<SENT sid="6" pm="."><plain>FAS <z:chebi fb="2" ids="33699">mRNA</z:chebi> was also upregulated with IFN-alpha stimulation but the fold induction was far lower than that of TRAIL <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, RPA revealed that the ratio of (TRAIL-R1 plus TRAIL-R2) to TRAIL-R3 was also increased after IFN-alpha stimulation </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, gene mutations of TRAIL-R1, TRAIL-R2 are infrequent in patients with <z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>And so is the TRAIL promoter for <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>These mutations seem unrelated to <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, disease progression, and response to IFN-alpha therapy in <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>A markedly high induction of TRAIL <z:chebi fb="2" ids="33699">mRNA</z:chebi> by IFN-alpha may have some relevance to IFN-alpha action in <z:mp ids='MP_0005481'>CML</z:mp> patients </plain></SENT>
</text></document>